RxSight (RXST) Insider Robert Palmisano Buys 37,037 Shares
Robert Palmisano purchased 37,037 shares of RxSight, Inc. on June 17, 2026.
Reviewed by automated data checks against the source filing. How we make and check alerts
Robert Palmisano bought 37,037 shares of RxSight, Inc. ($RXST) on June 17, 2026. The trade was reported to the SEC in a Form 4 filing.
Since the trade, $RXST is up 15.7% after 1 week, up 20.9% after 1 month and down 1.7% to date (from the $4.59 close on Jun 17, 2026).
RXST
RxSight, Inc.
Key Points
- Robert Palmisano acquired 37,037 shares of RxSight, Inc. on June 17, 2026.
- RxSight's stock is trading near $4.73, with a market cap of $195.8 million and a 52-week range of $4.48 to $14.25.
- Analysts from Needham and Wells Fargo maintain varied ratings, with price targets ranging from $9 to $13.
Get $RXST trade alerts by text
We text you when insiders, Congress or big funds trade $RXST. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated RxSight, Inc. alert may contain errors. Disclosures
On June 17, 2026, Robert Palmisano bought 37,037 shares of RxSight, Inc. (NasdaqGM: RXST). This insider transaction was not planned under a Rule 10b5-1 trading plan.
Other Institutional Activity in RxSight, Inc.
Among institutional investors, BlackRock, Inc. increased its holdings by 482,086 shares to a total of 3,187,092 shares, valued at approximately $19.6 million. Meanwhile, Millennium Management LLC and Artisan Partners Limited Partnership slightly reduced their positions by 69,579 and 98,580 shares, respectively. Nomura Holdings Inc. maintained its stake with 2,000,060 shares worth about $12.3 million, while No Street GP LP added 25,000 shares, bringing its total to 2,000,000 shares.
RxSight, Inc. Stock Down 9.0%
Shares of RxSight, Inc. traded around $4.73. The company has a market capitalization of about $195.8 million. With a forward P/E ratio of -8.45, the stock's beta is 1.134. The 52-week trading range is between $4.48 and $14.25, with a 50-day moving average of $6.09 and a 200-day moving average of $8.36. The company's current ratio is 10.2, and its quick ratio is 8.779, while the debt-to-equity ratio stands at 4.05.
Recent Earnings
RxSight reported revenue of $127.5 million, though it experienced a revenue decline of 18.5%. The company's net margin is -36.6%, and its return on equity is -17.1%. Earnings per share (EPS) is -$1.13. The next earnings report is expected on August 6, 2026.
Analysts Set New Price Targets
On May 7, 2026, Wells Fargo maintained a 'hold' rating with a price target of $9. Needham, on the same day, kept a 'buy' rating with a target of $11. The consensus among analysts suggests a mean target price of $8.79 across seven opinions.
About RxSight, Inc.
RxSight, Inc. is a healthcare company based in Aliso Viejo, California. It specializes in medical devices, particularly light adjustable intraocular lenses (LAL) for cataract surgery. The company's RxSight system allows doctors to customize visual acuity post-surgery. Dr. Ronald M. Kurtz M.D. leads the company, which employs around 461 people.
Bottom Line
Insider buying by Robert Palmisano at RxSight, Inc. highlights ongoing interest in the company's potential despite recent financial challenges. Investors often track such insider activities for insights into management's confidence in the business. As a reminder, these activities reflect past transactions and may not indicate current or future performance.
Related Filing Alerts
Source: Robert Palmisano's Form 4 filing on $RXST (Jun 17, 2026). Find the original filing: RXST Form 4 filings on SEC EDGAR. Written by software, not financial advice. How we make alerts